3,829 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by HighTower Advisors LLC

HighTower Advisors LLC acquired a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,829 shares of the biopharmaceutical company’s stock, valued at approximately $280,000.

A number of other hedge funds also recently bought and sold shares of ITCI. Wasatch Advisors LP grew its position in shares of Intra-Cellular Therapies by 3.5% in the third quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock valued at $281,601,000 after purchasing an additional 130,351 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Intra-Cellular Therapies by 21.2% during the second quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $205,470,000 after buying an additional 525,000 shares during the last quarter. Bellevue Group AG grew its holdings in Intra-Cellular Therapies by 0.6% in the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock valued at $181,873,000 after buying an additional 14,342 shares in the last quarter. Perceptive Advisors LLC increased its stake in shares of Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock worth $117,557,000 after acquiring an additional 661,052 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Intra-Cellular Therapies by 11.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,159,356 shares of the biopharmaceutical company’s stock worth $84,830,000 after acquiring an additional 116,494 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Insider Activity at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Michael Halstead sold 22,869 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ITCI shares. Royal Bank of Canada upped their price objective on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. JPMorgan Chase & Co. lifted their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Morgan Stanley upped their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, October 30th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies has an average rating of “Moderate Buy” and a consensus target price of $97.23.

Intra-Cellular Therapies Stock Up 0.7 %

Shares of ITCI opened at $84.00 on Tuesday. The firm’s 50 day moving average price is $83.84 and its 200 day moving average price is $77.58. The company has a market cap of $8.91 billion, a P/E ratio of -96.55 and a beta of 0.95. Intra-Cellular Therapies, Inc. has a fifty-two week low of $62.78 and a fifty-two week high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. During the same period in the prior year, the company posted ($0.25) earnings per share. The company’s revenue for the quarter was up 39.0% on a year-over-year basis. Research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.